Teva's Austedo meets in Phase III tardive dyskinesia study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said Austedo deutetrabenazine ( SD-809) met the primary endpoint in the Phase

Read the full 179 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE